BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Pharm Country

  Medidata Selected by ICON to Evolve Image Management and Accelerate Research Goals for Sponsors and Sites During Clinical Trials

  ICON will expand its use of the Medidata Clinical Cloud to include image management services for end-to-end digital control of the healthcare industry’s fastest growing data source.

  November 15, 2017

   · 

  3 min read
• Policy

  Inotrem Granted Access to Priority Medicines Scheme (PRIME) for Its Lead Compound MOTREM in the Treatment of Septic Shock

  The EMA’s PRIME status is granted to promising medicines that may offer a major therapeutic advantage over existing treatments or benefit patients with no treatment options.

  November 15, 2017

   · 

  2 min read
• French Biotech ERYTECH Enters the Nasdaq and Raises $144M

  Announced full exercise of underwriters’ option to purchase additional American Depositary Shares (ADSs) and Ordinary Shares, with closing expected to take place on or about November 16, 2017.

  November 15, 2017

   · 

  8 min read
• Business

  Outpost Medicine Appoints Scott Byrd as CEO and Raises $20M in Series A Financing Extension

  Byrd will be succeeding David Socks, Interim CEO and Co-founder of Outpost.

  November 15, 2017

   · 

  4 min read
• Business

  China Pharma Reports Third Quarter 2017 Financial Results

  Revenues were $3.2M and $3.1 million for the three months ended September 30, 2017 and 2016 respectively.

  November 15, 2017

   · 

  23 min read
• Business

  GeneNews Announces Q3-2017 Financial Results Provides Progress Update

  GeneNews today announced operational and financial results for the three-month period ended September 30, 2017, and provided a progress update on its business.

  November 15, 2017

   · 

  5 min read
• 

  FDA

  Astrazeneca Gets Another Boost With FDA Approval of Severe Asthma Drug

  The drug, in combination with abemaciclib, showed 16.4 Months of progression-free survival.

  November 15, 2017

   · 

  12 min read
• Business

  Xenetic Biosciences Reports 2017 Third Quarter Financial Results and Provides Corporate Update

  Net loss for the nine months ended September 30, 2017, was $8.0 million compared to a net loss of approximately $53.8 million for the same period in 2016.

  November 15, 2017

   · 

  10 min read
• Deals

  Invitae Completes Acquisition of CombiMatrix, Becoming a Leader in Family and Reproductive Health Genetic Information Services

  In connection with the closing, Invitae issued approximately $21.2M in shares of its common stock to former CombiMatrix securityholders, or approximately 2.7 million shares.

  November 15, 2017

   · 

  8 min read
• Business

  BIOREM Reports Significant Revenue and Income Growth for Third Quarter

  BIOREM today announced its results for the three and nine-month periods ended September 30, 2017.

  November 15, 2017

   · 

  3 min read